Jupiter, Fla.-based Envoy Therapeutics, Inc., a new drug discovery company, closed a $8m financing round. consisting of a private placement of its Series A Preferred Stock.
The round was led by 5AM Ventures, with participation from Takeda Research Investment and Roche Venture Fund.
Envoy will use the proceeds to discover and develop new treatments for neurological and psychiatric diseases.
Brad Margus, co-founder and Chief Executive Officer of Envoy, was reported as saying: “With the proceeds from this equity financing, we expect to demonstrate the power of our technology by delivering successful results in a select number of partnerships with global pharmaceutical companies and building our own portfolio of new drugs that may help millions of people”.
FinSMEs
15/10/2009